<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Assessment and management of depression in palliative care
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Assessment and management of depression in palliative care
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Assessment and management of depression in palliative care
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William Breitbart, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anna L Dickerman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan D Block, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter P Roy-Byrne, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jane Givens, MD, MSCE
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Solomon, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 25, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with advanced illness often experience psychological distress. While emotional distress is natural and expected in individuals experiencing serious illness and confronting the end of their lives, the differentiation between a normal and appropriate reaction to dying versus a more serious psychiatric disorder such as major depression can be clinically challenging.
        </p>
        <p>
         This topic reviews assessment and management of depression in patients receiving palliative care for serious illness. The basic principles of palliative care, assessment and management of other symptoms that are prevalent among patients with advanced illness, and psychosocial, existential, and spiritual issues in palliative care are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14240.html" rel="external">
          "Benefits, services, and models of subspecialty palliative care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2197.html" rel="external">
          "Overview of comprehensive patient assessment in palliative care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2196.html" rel="external">
          "Approach to symptom assessment in palliative care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2199.html" rel="external">
          "Overview of managing common non-pain symptoms in palliative care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2195.html" rel="external">
          "Psychosocial issues in advanced illness"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2198.html" rel="external">
          "Overview of spirituality in palliative care"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          SCOPE OF THE PROBLEM
         </span>
         <span class="headingEndMark">
          —
         </span>
         Depressive syndromes are a common mental health problem in palliative medicine, yet they are widely misunderstood, underdiagnosed, and undertreated [
         <a href="#rid1">
          1-5
         </a>
         ]. Data on the prevalence of moderate to severe depression in the last six months of life for patients with terminal cancer were provided by a unique observational cohort study of all cancer decedents in Ontario Canada between 2007 and 2009  (
         <a class="graphic graphic_figure graphicRef59669" href="/z/d/graphic/59669.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Clinicians often fail to recognize the extent of a patient's depression until too late in the course of the disease. As an example, in a survey of 1046 consecutive hospice patients, only 10 percent were prescribed antidepressants at some point during hospice care [
         <a href="#rid3">
          3
         </a>
         ]. Patients prescribed tricyclic antidepressants were nearly always underdosed, and three-fourths of those started on antidepressants died within two weeks.
        </p>
        <p>
         Among the many barriers to the recognition and treatment of psychological symptoms in patients with advanced illness are the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The mistaken belief that all patients facing or contemplating the end of life are "depressed"
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The clinician's lack of knowledge and skill at recognizing and treating major depression [
         <a href="#rid7">
          7
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fear of upsetting the patient or intruding at an emotionally vulnerable time
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The stigma associated with psychiatric diagnoses such as major depression
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Apprehension about possible drug-drug interactions with psychotropic agents
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When caring for patients with advanced illness, clinicians themselves may feel a sense of hopelessness that can lead to therapeutic nihilism [
         <a href="#rid8">
          8
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Burden of depression
         </span>
         <span class="headingEndMark">
          —
         </span>
         Psychological distress is a major cause of suffering among patients with advanced disease or terminal illness [
         <a href="#rid9">
          9,10
         </a>
         ]. Depressive syndromes are highly correlated with a reduced quality of life, greater difficulty in managing the course of the patient's illness, decreased adherence to treatment, and earlier admission to inpatient or hospice care [
         <a href="#rid1">
          1,11-16
         </a>
         ]. Depression also impairs the patient's capacity for pleasure, meaning, connection, and doing the emotional work of separating and saying goodbye; it amplifies pain and other symptoms, and causes anguish and worry in family members and friends [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          Depression, suicide, and desire for a hastened death
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with advanced illness who suffer from depressive syndromes are also at high risk of suicide and suicidal ideation, and they have an increased desire for a hastened death [
         <a href="#rid4">
          4,17-23
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1708.html" rel="external">
          "Suicidal ideation and behavior in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One study concluded that suicidal ideation was relatively infrequent in cancer and limited to those who were significantly depressed [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a review of psychiatric consultation data from Memorial Sloan-Kettering Cancer Center, one-third of suicidal cancer patients had major depression, and 50 percent were diagnosed with an adjustment disorder with features of both anxiety and depression at the time of evaluation [
         <a href="#rid21">
          21,24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although some studies suggest that hopelessness is a significantly better predictor of completed suicide than is depression alone [
         <a href="#rid25">
          25-27
         </a>
         ], others have found that a clinical diagnosis of depression, the severity of depressive symptoms, and a sense of hopelessness are all strong and independent predictors of a desire for hastened death in the terminally ill [
         <a href="#rid20">
          20,28
         </a>
         ]. Depression, hopelessness, and general psychological distress are also consistently associated with interest in physician-assisted dying and euthanasia; as many as 59 percent of patients requesting physician-assisted dying are depressed [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Prevalence of depression in palliative care
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of depressive syndromes in patients with advanced or terminal illness varies widely.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Cancer patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         The reported prevalence of major depression in individuals with cancer varies from 3 to 38 percent [
         <a href="#rid30">
          30-36
         </a>
         ]. This wide variability is explained by the lack of agreement as to appropriate diagnostic criteria to be used in the setting of advanced illness  (
         <a class="graphic graphic_table graphicRef81607" href="/z/d/graphic/81607.html" rel="external">
          table 1
         </a>
         ), differences in patient populations (ie, demographics, type and stage of disease, treatment versus no treatment), and variation in assessment methods. In general, rates are higher in populations with advanced cancer, greater levels of disability, and/or unrelieved pain [
         <a href="#rid33">
          33,35,37-39
         </a>
         ]. (See
         <a class="local">
          'Assessment and diagnosis'
         </a>
         below.)
        </p>
        <p>
         Even when the most stringent criteria are used, major depression is diagnosed in approximately 7 percent, and minor depression in 11 percent, of patients with advanced cancer [
         <a href="#rid33">
          33,38-40
         </a>
         ]. The reported prevalence of depression in terminally ill cancer patients is between 13 and 26 percent [
         <a href="#rid12">
          12,20,41,42
         </a>
         ]. These rates are significantly higher than one-month prevalence rates of depression in the general North American population, which range from 1.6 to 4.9 percent [
         <a href="#rid30">
          30,31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4858.html" rel="external">
          "Patients with cancer: Overview of the clinical features and diagnosis of psychiatric disorders", section on 'Prevalence of psychiatric comorbidity'
         </a>
         .)
        </p>
        <p>
         The clinical features, prevalence, and diagnosis of depressive disorders in patients with cancer are discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4858.html" rel="external">
          "Patients with cancer: Overview of the clinical features and diagnosis of psychiatric disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Non-cancer populations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Similarly, patients with other advanced medical illnesses also appear to have elevated rates of depression. Within non-cancer populations, depression has been identified in up to 27 percent of patients with end-stage kidney disease and those seeking to discontinue dialysis [
         <a href="#rid43">
          43,44
         </a>
         ], 20 to 40 percent of those with Parkinson disease [
         <a href="#rid45">
          45,46
         </a>
         ], 35 percent of patients with advanced multiple sclerosis [
         <a href="#rid47">
          47
         </a>
         ], and 22 to 46 percent of patients with advanced heart failure [
         <a href="#rid48">
          48,49
         </a>
         ]. Depression is also a common symptom in patients with AIDS, affecting 23 to 52 percent of those with end-stage disease [
         <a href="#rid50">
          50,51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4864.html" rel="external">
          "Depression, mania, and schizophrenia in patients with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1919.html" rel="external">
          "Kidney palliative care: Principles, benefits, and core components"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         An awareness of the specific risk factors for depressive disorders in patients receiving end-of-life care may facilitate early diagnosis and intervention [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Age and gender
         </span>
         <span class="headingEndMark">
          —
         </span>
         In several (but not all [
         <a href="#rid53">
          53
         </a>
         ]) studies, younger cancer patients have higher rates of depressive disorders and self-reported distress [
         <a href="#rid54">
          54-58
         </a>
         ]. While depression is twice as common in women as compared with men in the general population, gender is not consistently reported to be a risk factor for depression in cancer patients [
         <a href="#rid33">
          33,59
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Prior history of depression
         </span>
         <span class="headingEndMark">
          —
         </span>
         A past history of depression is a risk factor for major depression in cancer patients [
         <a href="#rid5">
          5,60
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Uncontrolled symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of uncontrolled symptoms, particularly pain, is a major risk factor for depression and suicide among patients with cancer [
         <a href="#rid61">
          61-63
         </a>
         ]. Some speculate that depression may result in an amplification of pain, while others suggest that it lessens the ability to tolerate the stress of physical symptoms [
         <a href="#rid64">
          64,65
         </a>
         ]. Thus, the causal pathway may be bidirectional [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Type of illness
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of depression also depends upon the patient's particular illness. Among cancer patients, those with head and neck and pancreatic cancers are at a particularly high risk [
         <a href="#rid33">
          33,67
         </a>
         ]. For patients with pancreatic cancer, psychiatric symptoms may precede the physical symptoms of the disease by several months, leading some to propose that tumor-induced changes in the neuroendocrine system may contribute to depression [
         <a href="#rid61">
          61,67,68
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Illness and treatment-related factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain factors associated with the patient's illness or its treatment may be associated with depression. Tumors arising within or metastasizing to the central nervous system can cause depression [
         <a href="#rid15">
          15,58,69,70
         </a>
         ]. In the case of pituitary tumors, this may be related to excess cortisol production [
         <a href="#rid71">
          71-73
         </a>
         ]. Metabolic complications such as hypercalcemia, often associated with breast and lung cancers, can also be associated with depression. (See
         <a class="medical medical_review" href="/z/d/html/832.html" rel="external">
          "Clinical manifestations of hypercalcemia"
         </a>
         .)
        </p>
        <p>
         Depression is common among patients with HIV/AIDS. HIV infection increases the risk of depression both through direct damage to subcortical brain areas and by disease-related chronic stress, social isolation, and intense demoralization. (See
         <a class="medical medical_review" href="/z/d/html/4860.html" rel="external">
          "Overview of the neuropsychiatric aspects of HIV infection and AIDS", section on 'Major Depression'
         </a>
         .)
        </p>
        <p>
         Other causes of depression in cancer patients include toxins created by a tumor, possibly autoimmune reactions [
         <a href="#rid74">
          74
         </a>
         ], viral infections, and nutritional deficiencies. Depression can also represent an adverse effect from certain treatments, including glucocorticoids; chemotherapy drugs (
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">
          vinblastine
         </a>
         , asparaginase, intrathecal
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , interferon, and
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         [
         <a href="#rid75">
          75-82
         </a>
         ]); as well as radiotherapy to the brain or head and neck [
         <a href="#rid83">
          83-87
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Existential concerns and spirituality
         </span>
         <span class="headingEndMark">
          —
         </span>
         The recognition of a life-threatening crisis brings existential concerns (unfulfilled ambitions, the meaning of life, maintaining dignity at the end of life) to the forefront [
         <a href="#rid1">
          1
         </a>
         ]. Existential suffering and deep personal anguish are some of the most distressing experiences that occur in the dying [
         <a href="#rid88">
          88
         </a>
         ]. The relationship between existential distress and depressive syndromes among the terminally ill is not well studied. In one study, existential distress (ie, concerns related to loss of meaning in life) showed a higher correlation with scores on depression scales than did items pertaining to physical symptoms, medical treatment, or social isolation [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
         Patients who have high levels of spiritual wellbeing tend to be less depressed. The inverse correlation between religious beliefs/spirituality and severity of depressive symptoms was shown in a sample of 162 terminally ill patients with cancer and AIDS [
         <a href="#rid89">
          89
         </a>
         ]. The beneficial aspects of religion related primarily to spiritual wellbeing rather than to formal religious practice. (See
         <a class="medical medical_review" href="/z/d/html/2195.html" rel="external">
          "Psychosocial issues in advanced illness"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2198.html" rel="external">
          "Overview of spirituality in palliative care"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          ASSESSMENT AND DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Screening for depression should be carried out in all palliative care patients given the high prevalence of symptoms. For patients with cancer, the American Society of Clinical Oncology has issued recommendations for the assessment and diagnosis of depression, endorsing practice guidelines from the Pan-Canadian Guideline on Screening, Assessment and Care of Psychosocial Distress (Depression, Anxiety) in Adults with Cancer [
         <a href="#rid90">
          90
         </a>
         ]. The recommendations state that every patient with cancer should be screened for depression when the initial diagnosis of cancer is made and periodically thereafter as clinically indicated, especially with changes in cancer or treatment status (eg, posttreatment, recurrence, or progression) as well as transition to palliative care. We agree with this recommendation.
        </p>
        <p>
         The two-item Patient Health Questionnaire (PHQ-2)  (
         <a class="graphic graphic_table graphicRef89663" href="/z/d/graphic/89663.html" rel="external">
          table 2
         </a>
         ) can be used to screen for depression. Patients who screen positive (a single "yes" response) should be interviewed to diagnose depression; the interview can be facilitated with the PHQ-9  (
         <a class="graphic graphic_table graphicRef59307" href="/z/d/graphic/59307.html" rel="external">
          table 3
         </a>
         ). Additional information about screening for depression is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/83887.html" rel="external">
          "Screening for depression in adults"
         </a>
         .)
        </p>
        <p>
         Depressed mood, sadness, grief, and anticipatory feelings of loss are all appropriate responses to advanced disease and dying. However, feelings of hopelessness, helplessness, worthlessness, guilt, lack of pleasure, and suicidal ideation (even mild or passive) are among the best indicators of depressive syndromes in these patients [
         <a href="#rid21">
          21,24,91
         </a>
         ]. Passive suicidal ideation ("I'd be better off dead") should be distinguished from active suicidal ideation ("I’m going to kill myself"). (See
         <a class="medical medical_review" href="/z/d/html/14684.html" rel="external">
          "Bereavement and grief in adults: Clinical features", section on 'Unipolar major depression'
         </a>
         .)
        </p>
        <p>
         A summary of some of the contrasting characteristics of normal grief versus depression in terminally ill patients is provided in a table  (
         <a class="graphic graphic_table graphicRef53062" href="/z/d/graphic/53062.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         There are two important caveats:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Feelings of hopelessness, helplessness, and guilt must be considered in the context of the patient's illness. Hopelessness may be difficult to interpret in the setting of a disease where there is no hope for cure or recovery [
         <a href="#rid27">
          27
         </a>
         ]. Furthermore, patients may feel helpless because of their physical condition, or there may be a sense of guilt if the illness is related to certain behaviors (eg, cirrhosis and hepatocellular cancer in alcoholics, lung cancer in smokers). Symptoms that seem out of proportion to the patient's actual situation should prompt concern for major depression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There is considerable overlap between the neurovegetative or somatic symptoms of major depression (eg, fatigue, insomnia, anorexia, and weight loss) and those associated with any serious illness and/or its treatment. This has led some to exclude these symptoms from diagnostic criteria for depression in medically ill patients, a subject that is discussed in detail below. (See
         <a class="local">
          'Criterion-based diagnosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Tools for assessment and diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are two major types of research methods that are available for the assessment of depression in advanced illness: criterion-based instruments, which may be based upon a diagnostic classification scheme or the outcome of a structured diagnostic interview, and self-report measures. The available tools are summarized in a table  (
         <a class="graphic graphic_table graphicRef66861" href="/z/d/graphic/66861.html" rel="external">
          table 5
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Criterion-based diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most widely used criteria to diagnose depression in non-terminally ill patients are those outlined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [
         <a href="#rid92">
          92
         </a>
         ]. If sufficient criteria are not met for the diagnosis of major depression, then patients may be classified as "adjustment disorder" with depressive features, or mood disorder secondary to medical condition.
        </p>
        <p>
         Small differences between investigators in the application of symptom severity thresholds (eg, the severity with which symptoms must be expressed before they are considered clinically significant) can result in large differences in prevalence rates for depression in studied populations. Furthermore, as noted previously, because somatic complaints in medically ill patients may also be attributable to the physical effects of the illness or its treatment, their use as diagnostic criteria can also affect the rate of diagnosis of major depression in medically ill patients, particularly when they are used in conjunction with a low-threshold symptom severity approach [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         Because of these issues, several general approaches to the diagnosis of major depression in the medically ill have evolved, which differ in how they deal with somatic symptoms and in the definition of symptom severity. These approaches are outlined in a table  (
         <a class="graphic graphic_table graphicRef81607" href="/z/d/graphic/81607.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         The most widely used is the substitutive approach of Endicott [
         <a href="#rid93">
          93
         </a>
         ]. The Endicott scale replaces four of the DSM-IV-TR somatic criteria thought most likely attributable to medical illness or its treatment (ie, change of weight/appetite, sleep disturbance, loss of energy/fatigue, difficulty thinking or concentrating) with cognitive substitutes (depressed appearance, social withdrawal, brooding/self-pity/pessimism, and lack of reactivity in situations that would normally be pleasurable)  (
         <a class="graphic graphic_table graphicRef60631" href="/z/d/graphic/60631.html" rel="external">
          table 6
         </a>
         ).
        </p>
        <p>
         Although the substitutive approach is used most often for research purposes, most experts agree that for clinical purposes, the use of a modified inclusive set of diagnostic criteria that incorporates both neurovegetative and psychological symptoms of depression, and emphasizes the presence of hopelessness, worthlessness, guilt, and suicidal ideation is most appropriate for the palliative care population [
         <a href="#rid1">
          1,94
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Self-report instruments
         </span>
         <span class="headingEndMark">
          —
         </span>
         Criterion-based diagnostic systems require an in-depth clinical interview. Self-report methods (eg, the PHQ-9  (
         <a class="graphic graphic_table graphicRef59307" href="/z/d/graphic/59307.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid95">
          95,96
         </a>
         ], 21-item Beck Depression Inventory [BDI] or the shorter 13-item scale [
         <a href="#rid97">
          97,98
         </a>
         ], or visual analog scales [
         <a href="#rid99">
          99,100
         </a>
         ]) may be used if a direct face-to-face interview is not feasible. However, these self-report scales are only a crude substitute for a careful diagnostic interview. The efficacy of these tools as a diagnostic aid in the palliative care setting is not as good as a brief interview directly addressing the commonly accepted diagnostic criteria. Situations where they might be useful include providing additional information in difficult cases, quantifying the severity of a depressive syndrome after initial diagnosis, or monitoring changes in depression over time.
        </p>
        <p>
         A self-report measure designed to differentiate between preparatory grief and depression in adults, the Terminally Ill Grief or Depression Scale (TIGDS), has been developed and validated in a small series of 47 adult inpatients [
         <a href="#rid101">
          101
         </a>
         ]. The tool is comprised of grief and depression subscales totaling 47 questions and is described as easy to administer and acceptable to patients. However, the TIGDS has not been tested in other clinical settings and requires validation in larger samples.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h3">
          Simple screening instruments
         </span>
         <span class="headingEndMark">
          —
         </span>
         A careful diagnostic interview remains the gold standard method for assessment of depression in medically ill patients [
         <a href="#rid8">
          8
         </a>
         ]. However, direct face-to-face interviews are time-consuming, thus limiting their usefulness in palliative care settings.
        </p>
        <p>
         More than 50 questionnaires have been developed to aid the detection of depression or severe distress, but most have been validated in primary care patients. Few have been studied specifically in palliative care settings [
         <a href="#rid102">
          102-104
         </a>
         ], and most of these are too long for routine use. Assessment of depression in advanced illness requires instruments that are not only valid and reliable but also minimally burdensome, acceptable to patients, and easy to administer and score. A detailed discussion of depression assessment in cancer patients is provided elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4858.html" rel="external">
          "Patients with cancer: Overview of the clinical features and diagnosis of psychiatric disorders", section on 'Assessment of psychiatric symptoms'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4858.html" rel="external">
          "Patients with cancer: Overview of the clinical features and diagnosis of psychiatric disorders", section on 'Depressive disorders'
         </a>
         .)
        </p>
        <p>
         Simple one- or two-question and other abbreviated assessments appear to be as effective as longer instruments in screening for depression in most  (
         <a class="graphic graphic_table graphicRef61549" href="/z/d/graphic/61549.html" rel="external">
          table 7
         </a>
         ) [
         <a href="#rid97">
          97,99,105-111
         </a>
         ] but not all studies [
         <a href="#rid112">
          112
         </a>
         ]. The single-item screen is adapted from the Schedule for Affective Disorders and Schizophrenia (SADS) depression criteria [
         <a href="#rid105">
          105
         </a>
         ] and consists simply of asking the question: "Have you been depressed most of the time for the past two weeks?"
        </p>
        <p>
         This method appears to be accurate for identifying patients who might qualify for a diagnosis of depression on the basis of a full interview covering all of the criterion symptoms, and thus is a useful screening tool to select patients who need further evaluation [
         <a href="#rid97">
          97-99,102,106,107,113,114
         </a>
         ].
        </p>
        <p>
         The utility of this approach was shown in a study of 200 palliative care in patients with terminal cancer that compared the performance of four brief screen measures for depression, including the single-item question "Are you depressed?", a two-item question assessing depressed mood and loss of interest or pleasure in activities, a visual analog scale (VAS) for mood based on the Memorial Pain Assessment Card [
         <a href="#rid107">
          107
         </a>
         ], and the BDI short version [
         <a href="#rid99">
          99
         </a>
         ]. Using a semi-structured diagnostic interview as the gold standard for diagnosis, the single-item interview (using a threshold stringency equivalent to patients feeling depressed "most of the time") outperformed both the BDI and the VAS. The two-item scale did not identify more depressed patients, and it characterized four patients as being depressed who were classified as not depressed after the full interview.
        </p>
        <p>
         The sensitivity and specificity of a single-item question as a screen for depression have been shown by others in diverse cohorts [
         <a href="#rid102">
          102,113,114
         </a>
         ], although conflicting results have been observed in palliative care populations in the United Kingdom [
         <a href="#rid104">
          104,112,115
         </a>
         ] and in Japan [
         <a href="#rid116">
          116
         </a>
         ]. This is perhaps not surprising. While some patients may readily verbalize that they are depressed, others, no matter how despairing, may never acknowledge it or may label it something else (eg, nervousness) [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
         Guidelines for distress management from the National Comprehensive Cancer Network (NCCN) suggest the use of a VAS (ranging from no distress to extreme distress) as well as patient self-report of depression, sadness, and loss of interest in usual activities (yes or no) as a screen for depression [
         <a href="#rid117">
          117
         </a>
         ]. Both methods are reasonable as screening tools.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Major depression in palliative care or terminally ill patients is treatable, although some data suggest that these patients may not be adequately managed. For example, one cross-sectional analysis of patients with cancer with depression (n = 1538) being treated in Scotland found that over 70 percent of those with depression were not receiving potentially effective therapy [
         <a href="#rid118">
          118
         </a>
         ].
        </p>
        <p>
         The more favorable side effect profile of newer antidepressants (eg, selective serotonin reuptake inhibitors [SSRIs] and serotonin-norepinephrine reuptake inhibitors [SNRIs]) has facilitated their use in older adults and the medically ill. Because treatment with these agents is relatively benign and well tolerated, clinicians should have a low threshold for initiating therapy. Psychostimulants, in comparison with other antidepressants, have a faster onset of activity and are the preferred initial option for palliative care patients whose life expectancy is less than two to four months or for those in need of urgent treatment.
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          General treatment principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         The first step in treating depression is to relieve uncontrolled symptoms, particularly pain. Although pain is most often an issue in the setting of cancer, patients who have diseases that are not usually considered painful (eg, cardiac disease) may also experience moderate to severe pain at the end of life [
         <a href="#rid119">
          119
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2795.html" rel="external">
          "Assessment of cancer pain"
         </a>
         .)
        </p>
        <p>
         All patients should have a complete medical evaluation to assess possible general medical contributors to depressed mood. (See
         <a class="local">
          'Illness and treatment-related factors'
         </a>
         above.)
        </p>
        <p>
         If depression persists once pain is controlled, and a potentially reversible general medical cause of depressed mood cannot be identified, specific therapy is warranted. Treatment should be tailored to the individual needs of the patient. In addition to drug therapy, effective psychosocial interventions include individual or group psychotherapy, hypnotherapy, cognitive-behavioral therapy (eg, relaxation training and biofeedback), existential therapy, and self-help groups [
         <a href="#rid120">
          120-124
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2831.html" rel="external">
          "Overview of complementary, alternative, and integrative medicine practices in oncology care, and potential risks and harm"
         </a>
         .)
        </p>
        <p>
         There are no randomized trials that specifically address the benefit of psychotherapy for palliative care patients with depression, and there are few that address pharmacologic treatment [
         <a href="#rid125">
          125
         </a>
         ]. As a result, therapy for depression in these patients is generally based upon the larger body of evidence on effective treatments in patients with cancer, or primary care populations with either no physical illness or less severe medical conditions. Although there is a lack of controlled trials to support the efficacy of combined therapy, most experts recommend an approach that combines supportive psychotherapy with patient and family education and judicious use of antidepressant medication [
         <a href="#rid8">
          8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4853.html" rel="external">
          "Management of psychiatric disorders in patients with cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">
          "Unipolar major depression in adults: Choosing initial treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14687.html" rel="external">
          "Unipolar depression in adults: Supportive psychotherapy"
         </a>
         .)
        </p>
        <p>
         It is important to note that for patients in palliative care, the data support the use of integrated treatment delivered collaboratively between disease-specific specialists, primary care providers, and mental health specialists. While best studied in patients with cancer [
         <a href="#rid126">
          126
         </a>
         ], it is likely that patients with other life-threatening illnesses may derive a similar benefit.
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          Psychosocial interventions
         </span>
         <span class="headingEndMark">
          —
         </span>
         A broad range of psychological interventions have been found to be effective for the treatment of major depression in a variety of patients, including those with cancer [
         <a href="#rid127">
          127-131
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4853.html" rel="external">
          "Management of psychiatric disorders in patients with cancer", section on 'Psychotherapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14612.html" rel="external">
          "Overview of psychotherapies"
         </a>
         .)
        </p>
        <p>
         Psychotherapy increases the effectiveness of drug therapy for major depression in older primary care patients [
         <a href="#rid132">
          132,133
         </a>
         ], and most experts recommend a combined approach in medically ill patients as well, despite the lack of evidence from randomized trials to support this practice. However, patients with severe depressive symptoms may be too immobilized and/or dysphoric to effectively engage in psychotherapy; such patients may first need to receive appropriate pharmacotherapy.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h3">
          Supportive psychotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The single most important aspect of psychotherapeutic support for depressed terminally ill patients is the therapeutic alliance between the patient and the primary medical caregiver [
         <a href="#rid134">
          134
         </a>
         ]. Optimally, this relationship will be one of mutual trust, respect, and sensitivity. Maintaining ongoing contact with the patient both ensures that symptoms and treatment efficacy will be continuously reevaluated and reassures the patient that they will not be abandoned throughout the course of the terminal illness.
        </p>
        <p>
         Supportive psychotherapy aims to support adaptive coping mechanisms, minimize maladaptive ones, and decrease adverse psychological reactions such as fear, shame, self-loathing, and withdrawal. The main components of psychotherapy are active listening, supportive verbal interventions, and occasional interpretation.
        </p>
        <p>
         Clinicians should elicit from the patient their concerns about death and the dying process but need not focus solely on the issue of death. Patients should be encouraged to talk about their lives and experiences, fears about the impact of illness on family members, and past experiences of coping with loss. Patients should be encouraged to freely talk about or ask questions about their prognosis, with their therapist taking an interested and interactive role in the discussion. Reassurance is useful when it is based on a specific understanding of the individual's status and is not clinically unrealistic.
        </p>
        <p>
         Supportive therapy can be provided by the primary medical caregiver, psychiatrist, psychologist, hospice nurse, or social worker, depending on time, interest, training, and the severity of the patient's condition. Sometimes, supportive psychotherapy alone is sufficient to treat depression. Treating major depression with supportive psychotherapy is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/14687.html" rel="external">
          "Unipolar depression in adults: Supportive psychotherapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h3">
          Structured cognitive therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cognitive-behavioral techniques, which focus on distorted thoughts that adversely affect mood, are often integrated into depression therapy. These approaches explore patients' beliefs about the cancer diagnosis and its treatment and attempt to elicit irrational or unhelpful thoughts that lead to feelings of helplessness and hopelessness. Therapy then leads to the correction of these maladaptive thoughts along with providing new coping skills (eg, relaxation). (See
         <a class="medical medical_review" href="/z/d/html/4853.html" rel="external">
          "Management of psychiatric disorders in patients with cancer", section on 'Cognitive-behavioral therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h3">
          Existential psychotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serious illness has a profound impact on the sense of self; the physical and psychological losses that are often part of the illness challenge one's sense of wholeness and integrity, which are key components of emotional health. Serious illness also challenges personal values of independence and control (which together form the construct of dignity) as well as self-determination and self-worth.
        </p>
        <p>
         Existential therapies such as dignity therapy [
         <a href="#rid135">
          135-139
         </a>
         ], meaning-centered psychotherapy [
         <a href="#rid140">
          140,141
         </a>
         ], and therapeutic life review [
         <a href="#rid142">
          142
         </a>
         ] may represent appropriate choices for some terminally ill patients who confront daily choices that affect quality of life and who often have questions about the meaning, purpose, and value of their lives. Such therapy can improve spiritual wellbeing, lessen sadness and depression, and sustain or enhance a sense of meaning, peace, and purpose at the end of life. (See
         <a class="medical medical_review" href="/z/d/html/2198.html" rel="external">
          "Overview of spirituality in palliative care", section on 'Spiritual distress and existential suffering'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2195.html" rel="external">
          "Psychosocial issues in advanced illness", section on 'Common issues for patients with advanced illness'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h2">
          Pharmacotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with psychotherapy, there is a general lack of high-quality evidence regarding the effectiveness of antidepressants in patients with major depression who are receiving end-of-life care [
         <a href="#rid124">
          124,125
         </a>
         ]. There are no randomized trials focusing on this population. However, randomized trials and meta-analyses have documented the efficacy of antidepressants in depressed patients with physical illness, including those with "life-threatening" physical illness [
         <a href="#rid143">
          143
         </a>
         ]. Furthermore, a systematic review of antidepressants for treatment of depression in palliative care, which included 25 placebo-controlled randomized trials, demonstrated significant benefit of treatment over placebo within four to five weeks, with continued improvement over time [
         <a href="#rid144">
          144
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4853.html" rel="external">
          "Management of psychiatric disorders in patients with cancer", section on 'Pharmacotherapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h3">
          Drug selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are several classes of antidepressants, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychostimulants (eg,
         <a class="drug drug_general" data-topicid="9341" href="/z/d/drug information/9341.html" rel="external">
          dextroamphetamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">
          methylphenidate
         </a>
         , and
         <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">
          modafinil
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         SSRIs (see
         <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">
          "Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tricyclic antidepressants (TCAs) and tetracyclic antidepressants (see
         <a class="medical medical_review" href="/z/d/html/1717.html" rel="external">
          "Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         SNRIs (see
         <a class="medical medical_review" href="/z/d/html/1713.html" rel="external">
          "Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serotonin modulators (eg,
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          nefazodone
         </a>
         ,
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         , and
         <a class="drug drug_general" data-topicid="16102" href="/z/d/drug information/16102.html" rel="external">
          vilazodone
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/1713.html" rel="external">
          "Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Atypical antidepressants (eg, agomelatine,
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         , and
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/1713.html" rel="external">
          "Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monoamine oxidase inhibitors (MAOIs), which are rarely used in palliative care (see
         <a class="medical medical_review" href="/z/d/html/1715.html" rel="external">
          "Monoamine oxidase inhibitors (MAOIs): Pharmacology, administration, safety, and side effects"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         The agents used most commonly in palliative care patients are psychostimulants, SSRIs, and TCAs  (
         <a class="graphic graphic_table graphicRef85673" href="/z/d/graphic/85673.html" rel="external">
          table 8
         </a>
         ). Although there is no evidence that any particular antidepressant or class of antidepressants is preferable for patients receiving end-of-life or palliative care, the 2008 clinical practice guidelines for initial treatment of depression in primary care patients from the American College of Physicians make a strong recommendation to initiate an SSRI, SNRI, or atypical antidepressant [
         <a href="#rid145">
          145
         </a>
         ]. The most compelling reason why SSRIs are usually selected for initial therapy in depressed primary care patients is not because of demonstrated greater efficacy but because of their more favorable side effect profile [
         <a href="#rid146">
          146,147
         </a>
         ] and the markedly lower danger with overdose. (See
         <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">
          "Unipolar major depression in adults: Choosing initial treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/295.html" rel="external">
          "Tricyclic antidepressant poisoning"
         </a>
         .)
        </p>
        <p>
         However, there is some evidence that TCAs might be preferred for severely depressed patients. In general, patients with severe depression are less likely to drop out of treatment trials because of unacceptable side effects when taking an SSRI as compared with a TCA, but they are more likely to drop out because of treatment inefficacy. Evidence-based European guidelines for management of depression in palliative cancer care do not endorse any one category of antidepressants for initial therapy [
         <a href="#rid148">
          148
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">
          "Unipolar major depression in adults: Choosing initial treatment"
         </a>
         .)
        </p>
        <p>
         In addition to these drugs, psychostimulants are an important option for treatment of depression at the end of life because, unlike classic antidepressants, they take effect quickly.
        </p>
        <p>
         For palliative care patients, the factors that influence the choice of initial agent in addition to side effect profile  (
         <a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">
          table 9
         </a>
         ) are the available timeframe for treatment, coexisting medical problems and symptoms, and pharmacologic properties (eg, half-life, potential for drug-drug interactions, and availability of liquid formulation):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         While patients with an anticipated life expectancy of several months can afford to wait one or two weeks for a TCA or SSRI to begin working (as long as immediate onset of action is not essential), those with a shorter remaining lifespan (or severe depression requiring urgent treatment) do better with rapidly acting psychostimulants [
         <a href="#rid149">
          149-153
         </a>
         ]. Psychostimulants can be useful for the treatment of depressive symptoms in patients who are weeks from death. Even patients who are extremely debilitated and fatigued may experience improvement in mood and energy within 24 to 48 hours of starting treatment  (
         <a class="graphic graphic_table graphicRef85673" href="/z/d/graphic/85673.html" rel="external">
          table 8
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Psychostimulants may also be useful as initial agents for patients with a relatively long estimated lifespan who have severe depression and require urgent treatment and a rapid response [
         <a href="#rid154">
          154
         </a>
         ]. An antidepressant such as an SSRI can be introduced concurrently and the dose increased to therapeutic levels over one to two weeks while the dose of the psychostimulant is gradually decreased.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Older adult patients and those with cardiovascular disease should avoid drugs that cause orthostatic hypotension (eg, TCAs)  (
         <a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">
          table 9
         </a>
         ). Similarly, because they lack anticholinergic effects, SSRIs are preferred for patients with slowed intestinal motility or urinary retention, as well as those who have stomatitis or chronic dry mouth secondary to chemotherapy or radiotherapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who are at risk for seizures or who may have a lower seizure threshold because of other medications,
         <a class="drug drug_general" data-topicid="9588" href="/z/d/drug information/9588.html" rel="external">
          maprotiline
         </a>
         (where available) and
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         should be avoided as they are associated with the highest seizure risk  (
         <a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">
          table 9
         </a>
         ). However, virtually any antidepressant can have a small effect on lowering the seizure threshold, and all agents should be used cautiously in patients with central nervous system (CNS) disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Side effects may sometimes be used to the patient's advantage. As an example, the depressed patient who is experiencing agitation or insomnia may benefit from the more sedating antidepressants (eg, TCAs,
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         , or
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          mirtazapine
         </a>
         )  (
         <a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">
          table 9
         </a>
         ). By contrast, patients with fatigue or psychomotor slowing may do better with compounds that have the least sedating effects (eg, SSRIs and psychostimulants).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to their antidepressant action, the TCAs have analgesic properties (as do SNRIs such as
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         and
         <a class="drug drug_general" data-topicid="8484" href="/z/d/drug information/8484.html" rel="external">
          duloxetine
         </a>
         ), and they potentiate the effects of opioid analgesics. Thus, patients who are experiencing pain, particularly neuropathic pain, may benefit from these agents alone or in combination with other drugs. (See
         <a class="medical medical_review" href="/z/d/html/2815.html" rel="external">
          "Cancer pain management: Role of adjuvant analgesics (coanalgesics)", section on 'Antidepressants'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Liquid formulations are available for some antidepressants (eg,
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         ,
         <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">
          escitalopram
         </a>
         ,
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          doxepin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">
          nortriptyline
         </a>
         ) and may be preferred for patients who cannot swallow pills.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rather than continuously experimenting with a range of different drugs, clinicians should become comfortable with prescribing a single drug from each class in order to become familiar with dosing regimens, actions, interactions, and side effects. Specific interactions of antidepressants with other medications may be determined using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on drug interactions.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h3">
          Selective serotonin reuptake inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most cases, SSRIs are preferred for first-line therapy. SSRIs are generally as effective as TCAs for the treatment of depression, and they have a wider margin of safety than TCAs in the event of an overdose.
        </p>
        <p>
         There are currently several SSRIs marketed in the United States:
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         ,
         <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">
          escitalopram
         </a>
         ,
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">
          fluvoxamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         (
         <a class="graphic graphic_table graphicRef85673" href="/z/d/graphic/85673.html" rel="external">
          table 8
         </a>
         ). All have similar efficacy but differ in pharmacokinetics, drug interactions, and side effect profile. Although SSRIs are generally well tolerated, dose-related side effects such as jitteriness, restlessness, anxiety, agitation, headache, sexual dysfunction, gastrointestinal symptoms (diarrhea and nausea), and insomnia are common and may be problematic in debilitated patients  (
         <a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">
          table 9
         </a>
         ). Headache and jitteriness often subside after the first four to seven days of antidepressant initiation. (See
         <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">
          "Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          Fluoxetine
         </a>
         was shown to significantly improve quality of life and depressive symptoms in patients with advanced cancer in two of the only controlled trials carried out in this population [
         <a href="#rid155">
          155,156
         </a>
         ]. However, the clinical use of this agent in palliative care is limited by its long half-life (it takes five to six weeks to reach steady state drug concentrations) and the potential for significant drug-drug interactions because it inhibits hepatic drug metabolizing enzymes such as cytochrome P450 [
         <a href="#rid157">
          157,158
         </a>
         ]. Specific interactions of fluoxetine and other SSRIs with other medications may be determined using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on drug interactions. The specific cytochrome enzymes that each SSRI and their metabolites potently or moderately inhibit are summarized elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">
          "Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Drug-drug interactions'
         </a>
         .)
        </p>
        <p>
         In contrast to the long half-life of
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         , steady state levels are reached in 4 to 14 days with
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">
          fluvoxamine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         . However, the advantages of a shorter half-life SSRI such as paroxetine and fluvoxamine in ill cancer patients is counterbalanced by the fact that a missed dose may result in fairly rapid and unpleasant withdrawal syndrome. This does not tend to happen with sertraline.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          Paroxetine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8474" href="/z/d/drug information/8474.html" rel="external">
          fluvoxamine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         are also likely to be better tolerated by terminally ill patients than other SSRIs because they have fewer active metabolites, which can accumulate and cause toxicity.
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          Citalopram
         </a>
         and
         <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">
          escitalopram
         </a>
         have significantly fewer interactions with hepatic metabolizing enzymes than the other SSRIs, making them appealing choices in patients who are on other medications where drug-drug interactions are a concern.
        </p>
        <p>
         As in older adults, the initial SSRI dose for patients with advanced or end-stage medical illness should be approximately one-half that used in otherwise healthy patients  (
         <a class="graphic graphic_table graphicRef85673" href="/z/d/graphic/85673.html" rel="external">
          table 8
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/1719.html" rel="external">
          "Diagnosis and management of late-life unipolar depression"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h3">
          Tricyclic antidepressants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many studies have demonstrated the efficacy of TCAs in depressed, medically ill patients, although none are controlled trials.
        </p>
        <p>
         Although TCAs are still used in terminally ill cancer patients, they are not as well tolerated as SSRIs because of their sedating and autonomic effects, which can be particularly troublesome for terminally ill patients  (
         <a class="graphic graphic_table graphicRef85673" href="/z/d/graphic/85673.html" rel="external">
          table 8
         </a>
         ). The major side effects are anticholinergic effects, including dry mouth, blurred vision, constipation, urinary retention, tachycardia, orthostatic hypotension, impaired memory, confusion, or delirium  (
         <a class="graphic graphic_table graphicRef62488" href="/z/d/graphic/62488.html" rel="external">
          table 9
         </a>
         ). These adverse effects can be particularly problematic for patients receiving other medications with anticholinergic properties. Such patients are at risk for developing anticholinergic delirium [
         <a href="#rid159">
          159
         </a>
         ].
         <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">
          Desipramine
         </a>
         and
         <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">
          nortriptyline
         </a>
         are less anticholinergic than other tricyclics.
        </p>
        <p>
         Older adults are particularly susceptible to memory impairment, confusion, and hallucinations. Sedation is a particular problem with the tertiary amine tricyclics (ie,
         <a class="drug drug_general" data-topicid="8554" href="/z/d/drug information/8554.html" rel="external">
          imipramine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         , and
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          doxepin
         </a>
         ), which can exacerbate the sedating effects of other medications [
         <a href="#rid149">
          149
         </a>
         ].
        </p>
        <p>
         Older patients and those with advanced medical illness have a higher likelihood of drug intolerance and drug-drug interactions. Specific interactions of these agents with other medications may be determined using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on drug interactions. (See
         <a class="medical medical_review" href="/z/d/html/1719.html" rel="external">
          "Diagnosis and management of late-life unipolar depression"
         </a>
         .)
        </p>
        <p>
         If TCAs are chosen as the initial agent for older patients, they should be started at low doses and slowly titrated  (
         <a class="graphic graphic_table graphicRef85673" href="/z/d/graphic/85673.html" rel="external">
          table 8
         </a>
         ). In order to minimize drug toxicity and more carefully guide the drug titration process, TCAs with well-established therapeutic plasma levels and generally better tolerance profiles, such as
         <a class="drug drug_general" data-topicid="9329" href="/z/d/drug information/9329.html" rel="external">
          desipramine
         </a>
         and
         <a class="drug drug_general" data-topicid="9711" href="/z/d/drug information/9711.html" rel="external">
          nortriptyline
         </a>
         , should be prescribed [
         <a href="#rid160">
          160
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1717.html" rel="external">
          "Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h3">
          Other antidepressants
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          Venlafaxine
         </a>
         is a potent SNRI  (
         <a class="graphic graphic_table graphicRef85673" href="/z/d/graphic/85673.html" rel="external">
          table 8
         </a>
         ). Its use in terminally ill depressed patients has not been studied, but its pharmacokinetic properties and generally well-tolerated side effect profile suggest that it is a potentially useful agent [
         <a href="#rid134">
          134
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1713.html" rel="external">
          "Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Venlafaxine'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9656" href="/z/d/drug information/9656.html" rel="external">
          Mirtazapine
         </a>
         has also been shown to be effective for improving multiple symptoms, depression, and quality of life in patients with advanced cancer, although it is relatively sedating [
         <a href="#rid161">
          161,162
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/85816.html" rel="external">
          "Atypical antidepressants: Pharmacology, administration, and side effects", section on 'Mirtazapine'
         </a>
         .)
        </p>
        <p>
         Similarly,
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         can be an effective antidepressant, but it is also sedating  (
         <a class="graphic graphic_table graphicRef85673" href="/z/d/graphic/85673.html" rel="external">
          table 8
         </a>
         ). It may be given at low doses to treat depressed cancer patients with insomnia, and it may also be useful for patients who require adjunct analgesic effects in addition to antidepressant effects [
         <a href="#rid134">
          134
         </a>
         ]. Trazodone has also been associated with priapism and should thus be used with caution in male patients [
         <a href="#rid163">
          163
         </a>
         ].
         <a class="drug drug_general" data-topicid="9684" href="/z/d/drug information/9684.html" rel="external">
          Nefazodone
         </a>
         has been associated with liver failure and probably should not be used in this patient population. (See
         <a class="medical medical_review" href="/z/d/html/86265.html" rel="external">
          "Serotonin modulators: Pharmacology, administration, and side effects", section on 'Trazodone'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2815.html" rel="external">
          "Cancer pain management: Role of adjuvant analgesics (coanalgesics)", section on 'Antidepressants'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          Bupropion
         </a>
         is not the first drug of choice for the treatment of depression in terminally ill patients, although it may be considered for patients who have a poor response to the trial of other antidepressants (see
         <a class="medical medical_review" href="/z/d/html/1716.html" rel="external">
          "Switching antidepressant medications in adults"
         </a>
         ). The energizing effects of bupropion are similar to the stimulant drugs  (
         <a class="graphic graphic_table graphicRef85673" href="/z/d/graphic/85673.html" rel="external">
          table 8
         </a>
         ) [
         <a href="#rid164">
          164,165
         </a>
         ]. However, it is contraindicated for cancer patients with CNS disorders, due to its association with increased incidence of seizures [
         <a href="#rid166">
          166
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/85816.html" rel="external">
          "Atypical antidepressants: Pharmacology, administration, and side effects", section on 'Bupropion'
         </a>
         .)
        </p>
        <p>
         Heterocyclic antidepressants have side effect profiles similar to those for the TCAs [
         <a href="#rid134">
          134
         </a>
         ]. As noted above,
         <a class="drug drug_general" data-topicid="9588" href="/z/d/drug information/9588.html" rel="external">
          maprotiline
         </a>
         (where available) should be avoided in patients with brain tumors and patients susceptible to seizures, as seizure incidence is increased with this medication [
         <a href="#rid167">
          167
         </a>
         ]. Mianserin, a serotonergic antidepressant with adjuvant analgesic properties, is widely used in Europe and Latin America but not available in the United States. It is safe and effective for the treatment of depression in cancer [
         <a href="#rid168">
          168
         </a>
         ].
        </p>
        <p>
         As a drug class, the MAOIs are generally considered a less desirable alternative for treating depression in the terminally ill, due to the large number of adverse interactions associated with these drugs [
         <a href="#rid149">
          149,169
         </a>
         ]. Thus, MAOIs are generally reserved in this patient population for those who have shown past preferential responses to them for treatment of their depression [
         <a href="#rid134">
          134
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1715.html" rel="external">
          "Monoamine oxidase inhibitors (MAOIs): Pharmacology, administration, safety, and side effects"
         </a>
         .)
        </p>
        <p>
         Although it is not a classic antidepressant, the triazolobenzodiazepine
         <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">
          alprazolam
         </a>
         is a mildly effective antidepressant as well as an anxiolytic and may be particularly useful in medically ill patients who have mixed symptoms of anxiety and depression [
         <a href="#rid123">
          123
         </a>
         ]. A meta-analysis of randomized trials comparing alprazolam with placebo in patients with major depression (not limited to patients in the palliative care population) found greater symptom response with alprazolam [
         <a href="#rid170">
          170
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h3">
          Psychostimulants
         </span>
         <span class="headingEndMark">
          —
         </span>
         The efficacy of psychostimulants (
         <a class="drug drug_general" data-topicid="9341" href="/z/d/drug information/9341.html" rel="external">
          dextroamphetamine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">
          methylphenidate
         </a>
         , and
         <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">
          modafinil
         </a>
         ) for the treatment of depression in medically ill patients is supported by small prospective controlled trials [
         <a href="#rid150">
          150,171-174
         </a>
         ]. The main benefit of these agents over TCAs and SSRIs is their more rapid onset of action (often within 24 to 48 hours). (See
         <a class="local">
          'Drug selection'
         </a>
         above.)
        </p>
        <p>
         Psychostimulants may also be helpful in cases where dysphoric mood is associated with opioid-related sedation, severe psychomotor slowing, and even mild cognitive impairment, because stimulants are often energizing and improve overall performance on neuropsychological testing in the medically ill [
         <a href="#rid172">
          172,173,175
         </a>
         ]. At relatively low doses, these medications also stimulate appetite, promote a sense of wellbeing, and relieve feelings of weakness and fatigue in cancer patients [
         <a href="#rid134">
          134
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2800.html" rel="external">
          "Prevention and management of side effects in patients receiving opioids for chronic pain", section on 'Somnolence and mental clouding'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2813.html" rel="external">
          "Cancer-related fatigue: Treatment"
         </a>
         .)
        </p>
        <p>
         Although generally well tolerated, side effects may include agitation, insomnia (particularly if administered within six to eight hours of bedtime), anxiety, and tremor. Cardiac decompensation can occur in older adult patients and in those with heart disease. Rarely, confusion or delirium may occur in older adults or cognitively impaired individuals.
        </p>
        <p>
         Side effects are uncommon but include headache, nausea, dry mouth, anorexia, and diarrhea.
         <a class="drug drug_general" data-topicid="10157" href="/z/d/drug information/10157.html" rel="external">
          Modafinil
         </a>
         has less sympathomimetic effects than amphetamines and is often a good choice for older patients. However, it has been associated with a mild increase in blood pressure and should be used cautiously in people with a history of arrhythmias or heart disease. (See
         <a class="medical medical_review" href="/z/d/html/7681.html" rel="external">
          "Treatment of narcolepsy in adults", section on 'Modafinil'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19692201">
         <span class="h3">
          Ketamine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Meta-analyses of randomized trials that compared intravenous
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         with placebo in physically healthy patients with treatment-resistant depression have found rapid, clinically moderate to large benefits with N-methyl-D-aspartate (NMDA) receptor antagonists, such as ketamine; however, the long-term benefits and risks are unknown. Case reports and one small placebo-controlled trial of intravenous ketamine also suggest that ketamine can rapidly improve depressive symptoms in patients with refractory depression in the setting of a terminal illness, particularly in the setting of chronic pain [
         <a href="#rid176">
          176-184
         </a>
         ]. However, the optimal selection of patients for this approach and the best way in which to administer ketamine in this situation are unclear. (See
         <a class="medical medical_review" href="/z/d/html/119992.html" rel="external">
          "Ketamine and esketamine for treating unipolar depression in adults: Administration, efficacy, and adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2815.html" rel="external">
          "Cancer pain management: Role of adjuvant analgesics (coanalgesics)", section on 'Ketamine and other NMDA receptor antagonists'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2710212763">
         <span class="h2">
          Emerging psychopharmacologic interventions
         </span>
        </p>
        <p class="headingAnchor" id="H3831541565">
         <span class="h3">
          Psilocybin-assisted psychotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Psilocybin is a Schedule I substance used only in research settings and is not approved by the US Food and Drug Administration (FDA) for any indication. Psilocybin safety has been tested over several decades (although it has not been studied in patients with brain cancer, psychotic disorders, or psychotic disorders in first-degree relatives) [
         <a href="#rid185">
          185
         </a>
         ]. The potential effectiveness of psychedelics has been investigated in several studies for cancer-related existential distress [
         <a href="#rid186">
          186
         </a>
         ]. Psilocybin-assisted psychotherapy specifically has been studied in randomized Phase II trials for the treatment of existential distress in patients with life-threatening cancer [
         <a href="#rid187">
          187-189
         </a>
         ] and unipolar major depression [
         <a href="#rid190">
          190
         </a>
         ], and in open trials for demoralized long-term AIDS survivors [
         <a href="#rid191">
          191
         </a>
         ] as well as treatment-resistant depression [
         <a href="#rid192">
          192
         </a>
         ], with promising results [
         <a href="#rid193">
          193-196
         </a>
         ], showing acute and sustained reductions in measures of depression and existential distress while also improving quality-of-life metrics such as psychologic and spiritual wellbeing.
        </p>
        <p>
         Additional information about treating unipolar major depression with psilocybin is discussed separately in the context of highly resistant depression. (See
         <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">
          "Unipolar depression in adults: Choosing treatment for resistant depression"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3323132798">
         <span class="h3">
          MDMA-assisted psychotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         3,4-Methylenedioxy​methamphetamine (MDMA) is a Schedule I substance and is only used in the context of research or expanded access (granted for compassionate use) [
         <a href="#rid197">
          197
         </a>
         ]. Recreational use of the substance (also known as ecstasy) has been associated with cardiotoxicity, neurotoxicity, and death [
         <a href="#rid198">
          198-200
         </a>
         ]. Adverse events in clinical trials have typically been transient, mild to moderate in severity, and have included muscle tightness, decreased appetite, nausea, hyperhidrosis, and feeling cold [
         <a href="#rid201">
          201
         </a>
         ]. MDMA-assisted psychotherapy has shown acute and sustained reduction of posttraumatic stress disorder (PTSD) symptoms in a Phase III clinical trial [
         <a href="#rid201">
          201
         </a>
         ], described in detail elsewhere (see
         <a class="medical medical_review" href="/z/d/html/117909.html" rel="external">
          "Posttraumatic stress disorder in adults: Treatment overview", section on 'Medications with limited supporting evidence'
         </a>
         ). Future directions in palliative care research could include its use for unipolar major depression, PTSD secondary to life-threatening diagnoses, and cancer recurrence fears.
        </p>
        <p class="headingAnchor" id="H1634591687">
         <span class="h2">
          Electroconvulsive therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is rarely necessary to use electroconvulsive therapy (ECT) for medically ill patients who have depression with psychotic features or in whom treatment with antidepressants is either ineffective or poses unacceptable side effects. ECT is safe for use in the medically ill, but its use in patients near the end of life may be inconsistent with the goal of providing noninvasive and nonintrusive comfort care [
         <a href="#rid202">
          202
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">
          "Unipolar depression in adults: Choosing treatment for resistant depression"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H33">
         <span class="h1">
          INDICATIONS FOR PSYCHIATRIC REFERRAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         When assessing and treating depression in palliative care patients, several circumstances should prompt referral to a psychiatrist for an in-depth assessment of the patient's judgment, decision-making capacity, and mood. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Uncertainty as to the psychiatric diagnosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of a major psychiatric disorder
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient is suicidal or requesting assisted suicide or euthanasia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient is psychotic (hallucinations, delusions) or delirious
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient is unresponsive to therapy with first-line antidepressants
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Significant family conflict interferes with wellbeing, treatment, or decision-making
        </p>
        <p>
        </p>
        <p>
         The approach to terminally ill patients who ask about hastening death is addressed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/95251.html" rel="external">
          "Medical aid in dying: Ethical and legal issues"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3352814331">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119531.html" rel="external">
          "Society guideline links: Palliative care"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28301074">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/16582.html" rel="external">
          "Patient education: Medical care during advanced illness (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16583.html" rel="external">
          "Patient education: Advance directives (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H34">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Depression is the most common mental health problem encountered in palliative medicine, yet it is widely misunderstood, underdiagnosed, and undertreated. Individuals who suffer from depression are at high risk of suicide and suicidal ideation, and they have an increased desire for a hastened death. Failure to diagnose and treat depression impairs the quality of life of dying patients and adds to their burden of suffering. (See
         <a class="local">
          'Scope of the problem'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Screening for depression should be carried out in all palliative care patients. Screening is conducted when the initial diagnosis of cancer is made and periodically thereafter as clinically indicated, especially with changes in cancer or treatment status (eg, posttreatment, recurrence, or progression), as well as transition to palliative care. (See
         <a class="local">
          'Assessment and diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Depressed mood, sadness, grief, and anticipatory feelings of loss are appropriate responses in patients with a serious, life-threatening illness. Feelings of hopelessness, helplessness, worthlessness, guilt, and suicidal ideation (even mild or passive) are among the best indicators of depressive disorders in such patients. (See
         <a class="local">
          'Assessment and diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A careful diagnostic interview is the gold standard method for assessing whether patients are clinically depressed. However, a simple single question ("Have you been depressed most of the time for the past two weeks?") and other abbreviated screening methods appear to be as effective as longer instruments in identifying those patients who require further assessment for depression. (See
         <a class="local">
          'Tools for assessment and diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Major depression in terminally ill patients is treatable. The first step in treating depression is to relieve uncontrolled symptoms, particularly pain. (See
         <a class="local">
          'General treatment principles'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Supportive psychotherapy can be provided by the primary medical caregiver, psychiatrist, psychologist, hospice nurse, or social worker. While supportive therapy may be sufficient to treat depression, most experts recommend an approach that combines supportive psychotherapy with patient and family education and judicious use of antidepressant medication. (See
         <a class="local">
          'Psychosocial interventions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinicians should have a low threshold to initiate pharmacologic treatment, even if the diagnosis of a depressive syndrome is in question, because both psychostimulants and newer drugs such as selective serotonin receptor inhibitors (SSRIs) are relatively safe, effective, and well tolerated. (See
         <a class="local">
          'Pharmacotherapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For moderately to severely depressed patients who have an estimated life expectancy of at least two to four months, we recommend both pharmacotherapy and psychotherapy (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ). For patients whose life expectancy is at least two to four months, we typically initiate therapy with an antidepressant and choose an SSRI rather than a tricyclic antidepressant (TCA) because of their wider safety margin. Patients with more acute depressive symptoms may also benefit from use of a psychostimulant. (See
         <a class="local">
          'Drug selection'
         </a>
         above and
         <a class="local">
          'Selective serotonin reuptake inhibitors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with a shorter life expectancy (less than two to four months), or who need urgent treatment, we suggest a psychostimulant rather than other drugs (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For patients who have an estimated life expectancy of longer than two to four months, an SSRI is then started, and the dose gradually titrated upwards, while the dose of the psychostimulant is gradually reduced. (See
         <a class="local">
          'Drug selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regardless of the initial agent chosen, the starting dose should be approximately one-half that used in non-terminally ill patients, and then slowly and carefully titrated. During this time, maintaining ongoing contact with the patient both ensures that symptoms and treatment efficacy will be continuously reevaluated, and it reassures the patient that they will not be abandoned throughout the course of the terminal illness. (See
         <a class="local">
          'Supportive psychotherapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among the indications for referral to a psychiatrist are the following (see
         <a class="local">
          'Indications for psychiatric referral'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Uncertainty as to the psychiatric diagnosis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         History of a major psychiatric disorder
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patient is suicidal or requesting assisted suicide or euthanasia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patient is psychotic (hallucinations, delusions) or delirious
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patient is unresponsive to therapy with first-line antidepressants
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Breitbart W, Bruera E, Chochinov H, Lynch M. Neuropsychiatric syndromes and psychological symptoms in patients with advanced cancer. J Pain Symptom Manage 1995; 10:131.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharpe M, Strong V, Allen K, et al. Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. Br J Cancer 2004; 90:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lloyd-Williams M, Friedman T, Rudd N. A survey of antidepressant prescribing in the terminally ill. Palliat Med 1999; 13:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Mahony S, Goulet J, Kornblith A, et al. Desire for hastened death, cancer pain and depression: report of a longitudinal observational study. J Pain Symptom Manage 2005; 29:446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer HA, Sinnott C, Seed PT. Depressive symptoms in advanced cancer. Part 2. Depression over time; the role of the palliative care professional. Palliat Med 2003; 17:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seow H, Barbera L, Sutradhar R, et al. Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol 2011; 29:1151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Passik SD, Dugan W, McDonald MV, et al. Oncologists' recognition of depression in their patients with cancer. J Clin Oncol 1998; 16:1594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Block SD. Assessing and managing depression in the terminally ill patient. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians - American Society of Internal Medicine. Ann Intern Med 2000; 132:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson KG, Chochinov HM, McPherson CJ, et al. Suffering with advanced cancer. J Clin Oncol 2007; 25:1691.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chochinov HM, Tataryn D, Clinch JJ, Dudgeon D. Will to live in the terminally ill. Lancet 1999; 354:816.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Portenoy RK, Thaler HT, Kornblith AB, et al. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 1994; 3:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson KG, Chochinov HM, Skirko MG, et al. Depression and anxiety disorders in palliative cancer care. J Pain Symptom Manage 2007; 33:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hinton J. Which patients with terminal cancer are admitted from home care? Palliat Med 1994; 8:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christakis NA. Timing of referral of terminally ill patients to an outpatient hospice. J Gen Intern Med 1994; 9:314.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pelletier G, Verhoef MJ, Khatri N, Hagen N. Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol 2002; 57:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001; 161:1849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tiernan E, Casey P, O'Boyle C, et al. Relations between desire for early death, depressive symptoms and antidepressant prescribing in terminally ill patients with cancer. J R Soc Med 2002; 95:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akechi T, Okamura H, Nishiwaki Y, Uchitomi Y. Predictive factors for suicidal ideation in patients with unresectable lung carcinoma. Cancer 2002; 95:1085.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akechi T, Okuyama T, Sugawara Y, et al. Suicidality in terminally ill Japanese patients with cancer. Cancer 2004; 100:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breitbart W, Rosenfeld B, Pessin H, et al. Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA 2000; 284:2907.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breitbart W. Suicide in cancer patients. Oncology (Williston Park) 1987; 1:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chochinov HM, Wilson KG, Enns M, et al. Desire for death in the terminally ill. Am J Psychiatry 1995; 152:1185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breitbart W, Rosenfeld B, Gibson C, et al. Impact of treatment for depression on desire for hastened death in patients with advanced AIDS. Psychosomatics 2010; 51:98.
          </a>
         </li>
         <li class="breakAll">
          Breitbart W. Cancer pain and suicide. In: Advances in Pain Research and Therapy, Foley KM, Bonica JJ, Ventafridda V, Callaway M (Eds), Raven Press, 1990. Vol 16, p.399.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beck AT, Kovacs M, Weissman A. Hopelessness and suicidal behavior. An overview. JAMA 1975; 234:1146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kovacs M, Beck AT, Weissman A. Hopelessness: an indicator of suicidal risk. Suicide 1975; 5:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbey JG, Rosenfeld B, Pessin H, Breitbart W. Hopelessness at the end of life: the utility of the hopelessness scale with terminally ill cancer patients. Br J Health Psychol 2006; 11:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lloyd-Williams M, Payne S, Reeve J, Dona RK. Thoughts of self-harm and depression as prognostic factors in palliative care patients. J Affect Disord 2014; 166:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emanuel EJ, Fairclough DL, Emanuel LL. Attitudes and desires related to euthanasia and physician-assisted suicide among terminally ill patients and their caregivers. JAMA 2000; 284:2460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Regier DA, Boyd JH, Burke JD Jr, et al. One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry 1988; 45:977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 1994; 151:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chochinov HM, Wilson KG, Enns M, Lander S. Prevalence of depression in the terminally ill: effects of diagnostic criteria and symptom threshold judgments. Am J Psychiatry 1994; 151:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 2004; :57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDaniel JS, Musselman DL, Porter MR, et al. Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry 1995; 52:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akechi T, Okuyama T, Sugawara Y, et al. Major depression, adjustment disorders, and post-traumatic stress disorder in terminally ill cancer patients: associated and predictive factors. J Clin Oncol 2004; 22:1957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hotopf M, Chidgey J, Addington-Hall J, Ly KL. Depression in advanced disease: a systematic review Part 1. Prevalence and case finding. Palliat Med 2002; 16:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bukberg J, Penman D, Holland JC. Depression in hospitalized cancer patients. Psychosom Med 1984; 46:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evans DL, Staab JP, Petitto JM, et al. Depression in the medical setting: biopsychological interactions and treatment considerations. J Clin Psychiatry 1999; 60 Suppl 4:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciaramella A, Poli P. Assessment of depression among cancer patients: the role of pain, cancer type and treatment. Psychooncology 2001; 10:156.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kathol RG, Mutgi A, Williams J, et al. Diagnosis of major depression in cancer patients according to four sets of criteria. Am J Psychiatry 1990; 147:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Power D, Kelly S, Gilsenan J, et al. Suitable screening tests for cognitive impairment and depression in the terminally ill--a prospective prevalence study. Palliat Med 1993; 7:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chochinov HM, Tataryn DJ, Wilson KG, et al. Prognostic awareness and the terminally ill. Psychosomatics 2000; 41:500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis 2007; 14:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen LM, Dobscha SK, Hails KC, et al. Depression and suicidal ideation in patients who discontinue the life-support treatment of dialysis. Psychosom Med 2002; 64:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66:996.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieberman A. Depression in Parkinson's disease -- a review. Acta Neurol Scand 2006; 113:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chwastiak L, Ehde DM, Gibbons LE, et al. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry 2002; 159:1862.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006; 48:1527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibbs JS, McCoy AS, Gibbs LM, et al. Living with and dying from heart failure: the role of palliative care. Heart 2002; 88 Suppl 2:ii36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Selwyn PA, Rivard M, Kappell D, et al. Palliative care for AIDS at a large urban teaching hospital: program description and preliminary outcomes. J Palliat Med 2003; 6:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook JA, Grey D, Burke J, et al. Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women. Am J Public Health 2004; 94:1133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrison J, Maguire P. Predictors of psychiatric morbidity in cancer patients. Br J Psychiatry 1994; 165:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matulonis UA. End of life issues in older patients. Semin Oncol 2004; 31:274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carroll BT, Kathol RG, Noyes R Jr, et al. Screening for depression and anxiety in cancer patients using the Hospital Anxiety and Depression Scale. Gen Hosp Psychiatry 1993; 15:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kathol RG, Noyes R Jr, Williams J, et al. Diagnosing depression in patients with medical illness. Psychosomatics 1990; 31:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levine PM, Silberfarb PM, Lipowski ZJ. Mental disorders in cancer patients: a study of 100 psychiatric referrals. Cancer 1978; 42:1385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noyes R Jr, Kathol RG, Debelius-Enemark P, et al. Distress associated with cancer as measured by the illness distress scale. Psychosomatics 1990; 31:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh D, Donnelly S, Rybicki L. The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients. Support Care Cancer 2000; 8:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeFlorio ML, Massie MJ. Review of depression in cancer: Gender differences. Depression 1995; 3:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes JE. Depressive illness and lung cancer. I. Depression before diagnosis. Eur J Surg Oncol 1985; 11:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelsen DP, Portenoy RK, Thaler HT, et al. Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 1995; 13:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glover J, Dibble SL, Dodd MJ, Miaskowski C. Mood states of oncology outpatients: does pain make a difference? J Pain Symptom Manage 1995; 10:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chochinov HM, Wilson KG. The euthanasia debate: attitudes, practices and psychiatric considerations. Can J Psychiatry 1995; 40:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiegel D, Bloom JR. Pain in metastatic breast cancer. Cancer 1983; 52:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson KG, Chochinov HM. Physician-assisted suicide. N Engl J Med 1996; 335:518.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiegel D, Sands S, Koopman C. Pain and depression in patients with cancer. Cancer 1994; 74:2570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boyd AD, Riba M. Depression and pancreatic cancer. J Natl Compr Canc Netw 2007; 5:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shakin EJ, Holland J. Depression and pancreatic cancer. J Pain Symptom Manage 1988; 3:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mainio A, Hakko H, Niemelä A, et al. Gender difference in relation to depression and quality of life among patients with a primary brain tumor. Eur Psychiatry 2006; 21:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Litofsky NS, Farace E, Anderson F Jr, et al. Depression in patients with high-grade glioma: results of the Glioma Outcomes Project. Neurosurgery 2004; 54:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weitzner MA, Kanfer S, Booth-Jones M. Apathy and pituitary disease: it has nothing to do with depression. J Neuropsychiatry Clin Neurosci 2005; 17:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly WF, Checkley SA, Bender DA, Mashiter K. Cushing's syndrome and depression--a prospective study of 26 patients. Br J Psychiatry 1983; 142:16.
          </a>
         </li>
         <li class="breakAll">
          Breitbart W. Endocrine-related psychiatric disorders. In: Handbook of Psychooncology: Psychological Care of the Patient with Cancer, Holland JC, Rowland JH (Eds), Oxford University Press, 1989. p.356.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown JH, Paraskevas F. Cancer and depression: cancer presenting with depressive illness: an autoimmune disease? Br J Psychiatry 1982; 141:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patten SB, Barbui C. Drug-induced depression: a systematic review to inform clinical practice. Psychother Psychosom 2004; 73:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devlen J, Maguire P, Phillips P, et al. Psychological problems associated with diagnosis and treatment of lymphomas. I: Retrospective study. Br Med J (Clin Res Ed) 1987; 295:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devlen J, Maguire P, Phillips P, Crowther D. Psychological problems associated with diagnosis and treatment of lymphomas. II: Prospective study. Br Med J (Clin Res Ed) 1987; 295:955.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stiefel FC, Breitbart WS, Holland JC. Corticosteroids in cancer: neuropsychiatric complications. Cancer Invest 1989; 7:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holland J, Fasanello S, Onuma T. Psychiatric symptoms associated with L-asparaginase administration. J Psychiatr Res 1974; 10:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams F, Quesada JR, Gutterman JU. Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 1984; 252:938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denicoff KD, Rubinow DR, Papa MZ, et al. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 1987; 107:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weddington WW Jr. Delirium and depression associated with amphotericin B. Psychosomatics 1982; 23:1076.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly C, Paleri V, Downs C, Shah R. Deterioration in quality of life and depressive symptoms during radiation therapy for head and neck cancer. Otolaryngol Head Neck Surg 2007; 136:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irwin PH, Kramer S, Diamond NH, et al. Sex differences in psychological distress during definitive radiation therapy for cancer. J Psychosoc Oncol 1986; 4:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sehlen S, Lenk M, Herschbach P, et al. Depressive symptoms during and after radiotherapy for head and neck cancer. Head Neck 2003; 25:1004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kohda R, Otsubo T, Kuwakado Y, et al. Prospective studies on mental status and quality of life in patients with head and neck cancer treated by radiation. Psychooncology 2005; 14:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armstrong CL, Gyato K, Awadalla AW, et al. A critical review of the clinical effects of therapeutic irradiation damage to the brain: the roots of controversy. Neuropsychol Rev 2004; 14:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boston P, Bruce A, Schreiber R. Existential suffering in the palliative care setting: an integrated literature review. J Pain Symptom Manage 2011; 41:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nelson CJ, Rosenfeld B, Breitbart W, Galietta M. Spirituality, religion, and depression in the terminally ill. Psychosomatics 2002; 43:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andersen BL, DeRubeis RJ, Berman BS, et al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J Clin Oncol 2014; 32:1605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Labisi O. Assessing for suicide risk in depressed geriatric cancer patients. J Psychosoc Oncol 2006; 24:43.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, 2013.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Endicott J. Measurement of depression in patients with cancer. Cancer 1984; 53:2243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Block SD. Psychological issues in end-of-life care. J Palliat Med 2006; 9:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kroenke K, Spitzer RL. The PHQ-9: a new depression and diagnostic severity measure. Psychiatr Ann 2002; 32:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beck AT, Beck RW. Screening depressed patients in family practice. A rapid technic. Postgrad Med 1972; 52:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess 1996; 67:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chochinov HM, Wilson KG, Enns M, Lander S. "Are you depressed?" Screening for depression in the terminally ill. Am J Psychiatry 1997; 154:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lees N, Lloyd-Williams M. Assessing depression in palliative care patients using the visual analogue scale: a pilot study. Eur J Cancer Care (Engl) 1999; 8:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Periyakoil VS, Kraemer HC, Noda A, et al. The development and initial validation of the Terminally Ill Grief or Depression Scale (TIGDS). Int J Methods Psychiatr Res 2005; 14:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lloyd-Williams M, Spiller J, Ward J. Which depression screening tools should be used in palliative care? Palliat Med 2003; 17:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holtom N, Barraclough J. Is the Hospital Anxiety and Depression Scale (HADS) useful in assessing depression in palliative care? Palliat Med 2000; 14:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lloyd-Williams M, Dennis M, Taylor F. A prospective study to compare three depression screening tools in patients who are terminally ill. Gen Hosp Psychiatry 2004; 26:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978; 35:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jefford M, Mileshkin L, Richards K, et al. Rapid screening for depression--validation of the Brief Case-Find for Depression (BCD) in medical oncology and palliative care patients. Br J Cancer 2004; 91:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishman B, Pasternak S, Wallenstein SL, et al. The Memorial Pain Assessment Card. A valid instrument for the evaluation of cancer pain. Cancer 1987; 60:1151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson JA, Crawford GB. Identifying palliative care patients with symptoms of depression: an algorithm. Palliat Med 2005; 19:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berwick DM, Murphy JM, Goldman PA, et al. Performance of a five-item mental health screening test. Med Care 1991; 29:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thekkumpurath P, Venkateswaran C, Kumar M, Bennett MI. Screening for psychological distress in palliative care: a systematic review. J Pain Symptom Manage 2008; 36:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell AJ. Are one or two simple questions sufficient to detect depression in cancer and palliative care? A Bayesian meta-analysis. Br J Cancer 2008; 98:1934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahoney J, Drinka TJ, Abler R, et al. Screening for depression: single question versus GDS. J Am Geriatr Soc 1994; 42:1006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watkins C, Daniels L, Jack C, et al. Accuracy of a single question in screening for depression in a cohort of patients after stroke: comparative study. BMJ 2001; 323:1159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lloyd-Williams M, Dennis M, Taylor F, Baker I. Is asking patients in palliative care, "are you depressed?" Appropriate? Prospective study. BMJ 2003; 327:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akechi T, Okuyama T, Sugawara Y, et al. Screening for depression in terminally ill cancer patients in Japan. J Pain Symptom Manage 2006; 31:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riba MB, Donovan KA, Andersen B, et al. Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019; 17:1229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker J, Hansen CH, Martin P, et al. Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data. Lancet Psychiatry 2014; 1:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators. JAMA 1995; 274:1591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiegel D, Bloom JR, Yalom I. Group support for patients with metastatic cancer. A randomized outcome study. Arch Gen Psychiatry 1981; 38:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiegel D, Bloom JR. Group therapy and hypnosis reduce metastatic breast carcinoma pain. Psychosom Med 1983; 45:333.
          </a>
         </li>
         <li class="breakAll">
          Massie MJ, Holland JC, Straker N. Psychotherapeutic interventions. In: Handbook of Psychooncology: Psychological Care of the Patient with Cancer, Holland JC, Rowland JH (Eds), Oxford University Press, 1989. p.455.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holland JC, Morrow GR, Schmale A, et al. A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms. J Clin Oncol 1991; 9:1004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisch M. Treatment of depression in cancer. J Natl Cancer Inst Monogr 2004; :105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ly KL, Chidgey J, Addington-Hall J, Hotopf M. Depression in palliative care: a systematic review. Part 2. Treatment. Palliat Med 2002; 16:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker J, Hansen CH, Martin P, et al. Integrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancer. Lancet Oncol 2014; 15:1168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheard T, Maguire P. The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses. Br J Cancer 1999; 80:1770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newell SA, Sanson-Fisher RW, Savolainen NJ. Systematic review of psychological therapies for cancer patients: overview and recommendations for future research. J Natl Cancer Inst 2002; 94:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devine EC, Westlake SK. The effects of psychoeducational care provided to adults with cancer: meta-analysis of 116 studies. Oncol Nurs Forum 1995; 22:1369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer TJ, Mark MM. Effects of psychosocial interventions with adult cancer patients: a meta-analysis of randomized experiments. Health Psychol 1995; 14:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stagg EK, Lazenby M. Best practices for the nonpharmacological treatment of depression at the end of life. Am J Hosp Palliat Care 2012; 29:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciechanowski P, Wagner E, Schmaling K, et al. Community-integrated home-based depression treatment in older adults: a randomized controlled trial. JAMA 2004; 291:1569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruce ML, Ten Have TR, Reynolds CF 3rd, et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial. JAMA 2004; 291:1081.
          </a>
         </li>
         <li class="breakAll">
          Wilson KG, Chochinov HM, de Faye BJ, Breitbart W. Assessment and management of depression in palliative care. In: Handbook of Psychiatry in Palliative Medicine, Chochinov HM, Breitbart W (Eds), Oxford University Press, 2000. p.2.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chochinov HM, Hack T, Hassard T, et al. Dignity therapy: a novel psychotherapeutic intervention for patients near the end of life. J Clin Oncol 2005; 23:5520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montross L, Winters KD, Irwin SA. Dignity therapy implementation in a community-based hospice setting. J Palliat Med 2011; 14:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chochinov HM, Kristjanson LJ, Breitbart W, et al. Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial. Lancet Oncol 2011; 12:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vuksanovic D, Green HJ, Dyck M, Morrissey SA. Dignity Therapy and Life Review for Palliative Care Patients: A Randomized Controlled Trial. J Pain Symptom Manage 2017; 53:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez M, Arantzamendi M, Belar A, et al. 'Dignity therapy', a promising intervention in palliative care: A comprehensive systematic literature review. Palliat Med 2017; 31:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breitbart W, Rosenfeld B, Pessin H, et al. Meaning-centered group psychotherapy: an effective intervention for improving psychological well-being in patients with advanced cancer. J Clin Oncol 2015; 33:749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breitbart W, Pessin H, Rosenfeld B, et al. Individual meaning-centered psychotherapy for the treatment of psychological and existential distress: A randomized controlled trial in patients with advanced cancer. Cancer 2018; 124:3231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keall RM, Clayton JM, Butow PN. Therapeutic life review in palliative care: a systematic review of quantitative evaluations. J Pain Symptom Manage 2015; 49:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rayner L, Price A, Evans A, et al. Antidepressants for depression in physically ill people. Cochrane Database Syst Rev 2010; :CD007503.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rayner L, Price A, Evans A, et al. Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis. Palliat Med 2011; 25:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qaseem A, Snow V, Denberg TD, et al. Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008; 149:725.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mulrow CD, Williams JW Jr, Chiquette E, et al. Efficacy of newer medications for treating depression in primary care patients. Am J Med 2000; 108:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005; 143:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rayner L, Price A, Hotopf M, Higginson IJ. The development of evidence-based European guidelines on the management of depression in palliative cancer care. Eur J Cancer 2011; 47:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burns MM, Eisendrath SJ. Dextroamphetamine treatment for depression in terminally ill patients. Psychosomatics 1994; 35:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olin J, Masand P. Psychostimulants for depression in hospitalized cancer patients. Psychosomatics 1996; 37:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macleod AD. Methylphenidate in terminal depression. J Pain Symptom Manage 1998; 16:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallace AE, Kofoed LL, West AN. Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients. Am J Psychiatry 1995; 152:929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry 2000; 61:436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng CG, Boks MP, Roes KC, et al. Rapid response to methylphenidate as an add-on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four-week, randomized, double-blinded, placebo-controlled study. Eur Neuropsychopharmacol 2014; 24:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisch MJ, Loehrer PJ, Kristeller J, et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol 2003; 21:1937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holland JC, Romano SJ, Heiligenstein JH, et al. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology 1998; 7:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics. J Clin Psychopharmacol 1990; 10:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pearson HJ. Interaction of fluoxetine with carbamazepine. J Clin Psychiatry 1990; 51:126.
          </a>
         </li>
         <li class="breakAll">
          Breitbart W, Passik SD. Psychiatric aspects of palliative care. In: Oxford Textbook of Palliative Medicine, Doyle D, Hanks GW, MacDonald (Eds), Oxford University Press, 1993.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol 1990; 10:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Theobald DE, Kirsh KL, Holtsclaw E, et al. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 2002; 23:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson DS. Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics 2000; 41:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson JW Jr, Ware MR, Blashfield RK. Psychotropic medication and priapism: a comprehensive review. J Clin Psychiatry 1990; 51:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shopsin B. Bupropion: a new clinical profile in the psychobiology of depression. J Clin Psychiatry 1983; 44:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cullum JL, Wojciechowski AE, Pelletier G, Simpson JS. Bupropion sustained release treatment reduces fatigue in cancer patients. Can J Psychiatry 2004; 49:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peck AW, Stern WC, Watkinson C. Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiatry 1983; 44:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dessain EC, Schatzberg AF, Woods BT, Cole JO. Maprotiline treatment in depression. A perspective on seizures. Arch Gen Psychiatry 1986; 43:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Heeringen K, Zivkov M. Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin. Br J Psychiatry 1996; 169:440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Preskorn SH, Burke M. Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatry 1992; 53 Suppl:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Marwijk H, Allick G, Wegman F, et al. Alprazolam for depression. Cochrane Database Syst Rev 2012; :CD007139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandez F, Adams F, Holmes VF, et al. Methylphenidate for depressive disorders in cancer patients. An alternative to standard antidepressants. Psychosomatics 1987; 28:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Webster L, Andrews M, Stoddard G. Modafinil treatment of opioid-induced sedation. Pain Med 2003; 4:135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rozans M, Dreisbach A, Lertora JJ, Kahn MJ. Palliative uses of methylphenidate in patients with cancer: a review. J Clin Oncol 2002; 20:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centeno C, Sanz A, Cuervo MA, et al. Multicentre, double-blind, randomised placebo-controlled clinical trial on the efficacy of methylphenidate on depressive symptoms in advanced cancer patients. BMJ Support Palliat Care 2012; 2:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stiefel F, Die Trill M, Berney A, et al. Depression in palliative care: a pragmatic report from the Expert Working Group of the European Association for Palliative Care. Support Care Cancer 2001; 9:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zanicotti CG, Perez D, Glue P. Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer. J Palliat Med 2012; 15:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stefanczyk-Sapieha L, Oneschuk D, Demas M. Intravenous ketamine "burst" for refractory depression in a patient with advanced cancer. J Palliat Med 2008; 11:1268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang C, Zhou ZQ, Yang JJ. Be prudent of ketamine in treating resistant depression in patients with cancer. J Palliat Med 2011; 14:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thangathurai D, Roby J, Roffey P. Treatment of resistant depression in patients with cancer with low doses of ketamine and desipramine. J Palliat Med 2010; 13:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kollmar R, Markovic K, Thürauf N, et al. Ketamine followed by memantine for the treatment of major depression. Aust N Z J Psychiatry 2008; 42:170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irwin SA, Iglewicz A. Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care. J Palliat Med 2010; 13:903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iglewicz A, Morrison K, Nelesen RA, et al. Ketamine for the treatment of depression in patients receiving hospice care: a retrospective medical record review of thirty-one cases. Psychosomatics 2015; 56:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jafarinia M, Afarideh M, Tafakhori A, et al. Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial. J Affect Disord 2016; 204:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh JB, Fedgchin M, Daly EJ, et al. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. Am J Psychiatry 2016; 173:816.
          </a>
         </li>
         <li class="breakAll">
          Ross S, Franco S, Reiff C, Agin-Liebes G. Psilocybin. In: Handbook of Medical Hallucinogens, Grob CS, Grigsby J (Eds), The Guilford Press, 2021. p.181.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross S. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. Int Rev Psychiatry 2018; 30:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol 2016; 30:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 2016; 30:1165.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grob CS, Danforth AL, Chopra GS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 2011; 68:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2021; 78:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson BT, Danforth A, Daroff PR, et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine 2020; 27:100538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 2016; 3:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agin-Liebes GI, Malone T, Yalch MM, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol 2020; 34:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carhart-Harris R, Giribaldi B, Watts R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med 2021; 384:1402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carhart-Harris RL, Bolstridge M, Day CMJ, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology (Berl) 2018; 235:399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross S, Agin-Liebes G, Lo S, et al. Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer. ACS Pharmacol Transl Sci 2021; 4:553.
          </a>
         </li>
         <li class="breakAll">
          Multidisciplinary Association for Psychedelic Studies. Press release: FDA agrees to expanded access program for MDMA-assisted psychotherapy for PTSD. 2020. Available at: https://maps.org/news/media/8008-press-release-fda-agrees-to-expanded-access-program-for-mdma-assisted-psychotherapy-for-ptsd (Accessed on September 22, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonsignore A, Barranco R, Morando A, et al. MDMA Induced Cardio-toxicity and Pathological Myocardial Effects: A Systematic Review of Experimental Data and Autopsy Findings. Cardiovasc Toxicol 2019; 19:493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guerreiro DF, Carmo AL, da Silva JA, et al. [Club drugs]. Acta Med Port 2011; 24:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers G, Elston J, Garside R, et al. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol Assess 2009; 13:iii.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 2021; 27:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Massie MJ, Holland JC. Depression and the cancer patient. J Clin Psychiatry 1990; 51 Suppl:12.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2205 Version 63.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7730685" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Neuropsychiatric syndromes and psychological symptoms in patients with advanced cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14735170" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10474711" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : A survey of antidepressant prescribing in the terminally ill.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15904747" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Desire for hastened death, cancer pain and depression: report of a longitudinal observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14594151" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Depressive symptoms in advanced cancer. Part 2. Depression over time; the role of the palliative care professional.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21300920" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Trajectory of performance status and symptom scores for patients with cancer during the last six months of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9552071" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Oncologists' recognition of depression in their patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10651602" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Assessing and managing depression in the terminally ill patient. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians - American Society of Internal Medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17470861" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Suffering with advanced cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10485723" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Will to live in the terminally ill.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7920492" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Symptom prevalence, characteristics and distress in a cancer population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17280918" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Depression and anxiety disorders in palliative cancer care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7952370" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Which patients with terminal cancer are admitted from home care?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8077995" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Timing of referral of terminally ill patients to an outpatient hospice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12125966" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11493126" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12151487" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Relations between desire for early death, depressive symptoms and antidepressant prescribing in terminally ill patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12209695" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Predictive factors for suicidal ideation in patients with unresectable lung carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14692039" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Suicidality in terminally ill Japanese patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11147988" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3079476" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Suicide in cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7625468" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Desire for death in the terminally ill.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20332284" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Impact of treatment for depression on desire for hastened death in patients with advanced AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20332284" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Impact of treatment for depression on desire for hastened death in patients with advanced AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1242427" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Hopelessness and suicidal behavior. An overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1224378" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Hopelessness: an indicator of suicidal risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16643692" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Hopelessness at the end of life: the utility of the hopelessness scale with terminally ill cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25012448" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Thoughts of self-harm and depression as prognostic factors in palliative care patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11074775" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Attitudes and desires related to euthanasia and physician-assisted suicide among terminally ill patients and their caregivers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3263101" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8010383" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7511875" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Prevalence of depression in the terminally ill: effects of diagnostic criteria and symptom threshold judgments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15263042" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Prevalence of depression in patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7848055" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Depression in patients with cancer. Diagnosis, biology, and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15143090" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Major depression, adjustment disorders, and post-traumatic stress disorder in terminally ill cancer patients: associated and predictive factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11969152" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Depression in advanced disease: a systematic review Part 1. Prevalence and case finding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6739680" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Depression in hospitalized cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10086482" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Depression in the medical setting: biopsychological interactions and treatment considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11268142" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Assessment of depression among cancer patients: the role of pain, cancer type and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2375435" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Diagnosis of major depression in cancer patients according to four sets of criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8261189" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Suitable screening tests for cognitive impairment and depression in the terminally ill--a prospective prevalence study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11110113" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Prognostic awareness and the terminally ill.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17200048" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The prevalence of symptoms in end-stage renal disease: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12461194" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Depression and suicidal ideation in patients who discontinue the life-support treatment of dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16606910" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16367891" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Depression in Parkinson's disease -- a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12411220" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17045884" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12213799" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Living with and dying from heart failure: the role of palliative care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14509496" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Palliative care for AIDS at a large urban teaching hospital: program description and preliminary outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15226133" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Depressive symptoms and AIDS-related mortality among a multisite cohort of HIV-positive women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7866674" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Predictors of psychiatric morbidity in cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15112156" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : End of life issues in older patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8472942" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Screening for depression and anxiety in cancer patients using the Hospital Anxiety and Depression Scale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2247573" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Diagnosing depression in patients with medical illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/698920" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Mental disorders in cancer patients: a study of 100 psychiatric referrals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2388986" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Distress associated with cancer as measured by the illness distress scale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10789956" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The symptoms of advanced cancer: relationship to age, gender, and performance status in 1,000 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Review of depression in cancer: Gender differences
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3987908" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Depressive illness and lung cancer. I. Depression before diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7884435" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Pain and depression in patients with newly diagnosed pancreas cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7730684" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Mood states of oncology outpatients: does pain make a difference?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8681256" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The euthanasia debate: attitudes, practices and psychiatric considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6861077" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Pain in metastatic breast cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8676956" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Physician-assisted suicide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7923013" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Pain and depression in patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17239331" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Depression and pancreatic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3057080" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Depression and pancreatic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16140507" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Gender difference in relation to depression and quality of life among patients with a primary brain tumor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14744282" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Depression in patients with high-grade glioma: results of the Glioma Outcomes Project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15939968" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Apathy and pituitary disease: it has nothing to do with depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6831125" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Cushing's syndrome and depression--a prospective study of 26 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6831125" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Cushing's syndrome and depression--a prospective study of 26 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6182940" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Cancer and depression: cancer presenting with depressive illness: an autoimmune disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15184715" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Drug-induced depression: a systematic review to inform clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3119123" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Psychological problems associated with diagnosis and treatment of lymphomas. I: Retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3119124" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Psychological problems associated with diagnosis and treatment of lymphomas. II: Prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2695230" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Corticosteroids in cancer: neuropsychiatric complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4531491" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Psychiatric symptoms associated with L-asparaginase administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6748198" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3497595" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7178410" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Delirium and depression associated with amphotericin B.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17210344" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Deterioration in quality of life and depressive symptoms during radiation therapy for head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Sex differences in psychological distress during definitive radiation therapy for cancer
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14648859" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Depressive symptoms during and after radiotherapy for head and neck cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15655808" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Prospective studies on mental status and quality of life in patients with head and neck cancer treated by radiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15260139" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : A critical review of the clinical effects of therapeutic irradiation damage to the brain: the roots of controversy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21145202" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Existential suffering in the palliative care setting: an integrated literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12075036" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Spirituality, religion, and depression in the terminally ill.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24733793" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16803751" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Assessing for suicide risk in depressed geriatric cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16803751" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Assessing for suicide risk in depressed geriatric cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6704912" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Measurement of depression in patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16752981" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Psychological issues in end-of-life care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11556941" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : The PHQ-9: validity of a brief depression severity measure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : The PHQ-9: a new depression and diagnostic severity measure
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4635613" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Screening depressed patients in family practice. A rapid technic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8991972" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9137124" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : "Are you depressed?" Screening for depression in the terminally ill.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10889619" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Assessing depression in palliative care patients using the visual analogue scale: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16395873" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : The development and initial validation of the Terminally Ill Grief or Depression Scale (TIGDS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12597464" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Which depression screening tools should be used in palliative care?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10858831" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Is the Hospital Anxiety and Depression Scale (HADS) useful in assessing depression in palliative care?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15474638" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : A prospective study to compare three depression screening tools in patients who are terminally ill.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/678037" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : A diagnostic interview: the schedule for affective disorders and schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15305199" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Rapid screening for depression--validation of the Brief Case-Find for Depression (BCD) in medical oncology and palliative care patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3300951" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : The Memorial Pain Assessment Card. A valid instrument for the evaluation of cancer pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15984500" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Identifying palliative care patients with symptoms of depression: an algorithm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1593914" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1994148" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Performance of a five-item mental health screening test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18495416" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Screening for psychological distress in palliative care: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18506146" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Are one or two simple questions sufficient to detect depression in cancer and palliative care? A Bayesian meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8064088" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Screening for depression: single question versus GDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11711407" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Accuracy of a single question in screening for depression in a cohort of patients after stroke: comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12919988" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Is asking patients in palliative care, "are you depressed?" Appropriate? Prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16442477" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Screening for depression in terminally ill cancer patients in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31590149" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Distress Management, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26360998" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Prevalence, associations, and adequacy of treatment of major depression in patients with cancer: a cross-sectional analysis of routinely collected clinical data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7474243" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7235853" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Group support for patients with metastatic cancer. A randomized outcome study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6622622" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Group therapy and hypnosis reduce metastatic breast carcinoma pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6622622" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Group therapy and hypnosis reduce metastatic breast carcinoma pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2033413" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : A randomized clinical trial of alprazolam versus progressive muscle relaxation in cancer patients with anxiety and depressive symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15263050" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Treatment of depression in cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12132540" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Depression in palliative care: a systematic review. Part 2. Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25175097" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Integrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10468295" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11959890" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Systematic review of psychological therapies for cancer patients: overview and recommendations for future research.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8539178" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : The effects of psychoeducational care provided to adults with cancer: meta-analysis of 116 studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7789344" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Effects of psychosocial interventions with adult cancer patients: a meta-analysis of randomized experiments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21727149" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Best practices for the nonpharmacological treatment of depression at the end of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15069044" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Community-integrated home-based depression treatment in older adults: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14996777" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14996777" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16110012" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Dignity therapy: a novel psychotherapeutic intervention for patients near the end of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21548823" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Dignity therapy implementation in a community-based hospice setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21741309" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27810568" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Dignity Therapy and Life Review for Palliative Care Patients: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27566756" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : 'Dignity therapy', a promising intervention in palliative care: A comprehensive systematic literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25646186" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Meaning-centered group psychotherapy: an effective intervention for improving psychological well-being in patients with advanced cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29757459" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Individual meaning-centered psychotherapy for the treatment of psychological and existential distress: A randomized controlled trial in patients with advanced cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25261637" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Therapeutic life review in palliative care: a systematic review of quantitative evaluations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20238354" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Antidepressants for depression in physically ill people.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20935027" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19017591" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Using second-generation antidepressants to treat depressive disorders: a clinical practice guideline from the American College of Physicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11059441" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Efficacy of newer medications for treating depression in primary care patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16172440" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21211961" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : The development of evidence-based European guidelines on the management of depression in palliative cancer care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8134533" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Dextroamphetamine treatment for depression in terminally ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8600496" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Psychostimulants for depression in hospitalized cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9769622" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Methylphenidate in terminal depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7755127" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10901342" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24503279" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Rapid response to methylphenidate as an add-on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: a four-week, randomized, double-blinded, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12743146" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9741068" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1968472" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2353956" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Interaction of fluoxetine with carbamazepine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2353956" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : Interaction of fluoxetine with carbamazepine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2140373" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12007762" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10906359" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2211542" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Psychotropic medication and priapism: a comprehensive review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6406445" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : Bupropion: a new clinical profile in the psychobiology of depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15065748" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Bupropion sustained release treatment reduces fatigue in cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6406457" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3942475" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Maprotiline treatment in depression. A perspective on seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8894194" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : Pharmacological treatment of depression in cancer patients. A placebo-controlled study of mianserin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1522080" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Somatic therapy for major depressive disorder: selection of an antidepressant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22786504" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Alprazolam for depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3432548" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Methylphenidate for depressive disorders in cancer patients. An alternative to standard antidepressants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12873263" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Modafinil treatment of opioid-induced sedation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11773187" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Palliative uses of methylphenidate in patients with cancer: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24654216" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Multicentre, double-blind, randomised placebo-controlled clinical trial on the efficacy of methylphenidate on depressive symptoms in advanced cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11680829" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Depression in palliative care: a pragmatic report from the Expert Working Group of the European Association for Palliative Care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22468772" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Mood and pain responses to repeat dose intramuscular ketamine in a depressed patient with advanced cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19021495" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Intravenous ketamine "burst" for refractory depression in a patient with advanced cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21592028" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Be prudent of ketamine in treating resistant depression in patients with cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20178430" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Treatment of resistant depression in patients with cancer with low doses of ketamine and desipramine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18197514" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Ketamine followed by memantine for the treatment of major depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20636166" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Oral ketamine for the rapid treatment of depression and anxiety in patients receiving hospice care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25616995" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Ketamine for the treatment of depression in patients receiving hospice care: a retrospective medical record review of thirty-one cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27317968" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Efficacy and safety of oral ketamine versus diclofenac to alleviate mild to moderate depression in chronic pain patients: A double-blind, randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27056608" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27056608" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30102082" id="rid185" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          186 : Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27909165" id="rid186" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          187 : Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27909164" id="rid187" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          188 : Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20819978" id="rid188" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          189 : Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33146667" id="rid189" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          190 : Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33150319" id="rid190" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          191 : Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27210031" id="rid191" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          192 : Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31916890" id="rid192" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          193 : Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33852780" id="rid193" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          194 : Trial of Psilocybin versus Escitalopram for Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29119217" id="rid194" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          195 : Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33860185" id="rid195" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          196 : Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33860185" id="rid196" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          197 : Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31073690" id="rid197" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          198 : MDMA Induced Cardio-toxicity and Pathological Myocardial Effects: A Systematic Review of Experimental Data and Autopsy Findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22525626" id="rid198" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          199 : [Club drugs].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19195429" id="rid199" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          200 : The harmful health effects of recreational ecstasy: a systematic review of observational evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33972795" id="rid200" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          201 : MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2195008" id="rid201" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          202 : Depression and the cancer patient.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
